drugset / Trial / NCT01189513

SCH-900105 in Recurrent Glioblastoma

NCT01189513

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of SCH 900105 that can be given to patients with glioblastoma before surgery. The safety of this drug will also be studied.

Timeline

Start
2010-08
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ficlatuzumab Monoclonal antibody 10 mg/kg Intravenous

Indications